Fusaroli M.; Simonsen A.; Borrie S.A.; Low D.M.; Parola A.; Raschi E.; Poluzzi E.; Fusaroli R., Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System, «JOURNAL OF SPEECH, LANGUAGE, AND HEARING RESEARCH», 2023, 66, pp. 3242 - 3259 [articolo]Open Access
DiVito L.; Mazzoni S.; Belotti L.M.B.; Poluzzi E.; Baldin E.; Zenesini C.; Bisulli F.; Tinuper P.; Mostacci B., Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study, «EPILEPSIA», 2023, 64, pp. 910 - 918 [articolo]
Fusaroli M.; Salvo F.; Bernardeau C.; Idris M.; Dolladille C.; Pariente A.; Poluzzi E.; Raschi E.; Khouri C., Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study, «DRUG SAFETY», 2023, 46, pp. 857 - 866 [articolo]Open Access
Zito S.; Poluzzi E.; Pierantozzi A.; Onder G.; Da Cas R.; Ippoliti I.; Lunghi C.; Cangini A.; Trotta F., Medication use in Italian nursing homes: preliminary results from the national monitoring system, «FRONTIERS IN PHARMACOLOGY», 2023, 14, Article number: 1128605, pp. 1 - 10 [articolo]Open Access
Ahmadizar F.; Luxi N.; Raethke M.; Schmikli S.; Riefolo F.; Saraswati P.W.; Bucsa C.; Osman A.; Liddiard M.; Maques F.B.; Petrelli G.; Sonderlichova S.; Thurin N.H.; Villalobos F.; Trifiro G.; Sturkenboom M.; Moretti U.; Bellitto C.; Ciccimarra F.; Gonella L.A.; Arzenton E.; Chiamulera C.; Lora R.; Bellantuono D.; Sabaini A.; Firenze A.; Zodda D.; Guidotti F.; Zappone M.; Alagna B.; Cutroneo P.M.; Minore C.; Costantino C.; Vitale F.; D'Alessandro G.; Morreale I.; Marsala L.; Farinella D.; Bavetta S.; Fantini M.P.; Reno C.; Raschi E.; Poluzzi E.; Sapigni E.; Potenza A.M.; Podetti D.; Nikitina V.; Ricciardelli R.; Mogheiseh N.; Croce S.; Paltrinieri B.; Castellani S.; Sangiorgi E.; Selleri M.; Lucchesi S.; Catucci G.; Savini D.; Sacripanti C.; Faccioli M.; Romio M.S.; Rossi L.; Radici S.; Negri G.; Fares L.; Ajolfi C.; Fadda A.; Chiarello A.; Pieraccini F.; Gavioli B.; Palazzi S.; Tuccori M.; Vannacci A.; Bonaiuti R.; Ravaldi C.; Lombardi N.; Crescioli G.; Gori F.; Tessari R.; Zandona E, Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials, «DRUG SAFETY», 2023, 46, pp. 575 - 585 [articolo]Open Access
Raschi, Emanuel; Poluzzi, Elisabetta; De Ponti, Fabrizio, Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2023, 89, pp. 2365 - 2368 [replica/breve intervento]
Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Poluzzi E., The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2023, 89, pp. 2020 - 2027 [articolo]Open Access
Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System, «CANCERS», 2022, 14, Article number: 4610, pp. 1 - 13 [articolo]Open Access
Gaimari A.; Fusaroli M.; Raschi E.; Baldin E.; Vignatelli L.; Nonino F.; De Ponti F.; Mandrioli J.; Poluzzi E., Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System, «DRUG SAFETY», 2022, 45, pp. 663 - 673 [articolo]Open Access
Selke Krulichova I.; Selke G.W.; Bennie M.; Hajiebrahimi M.; Nyberg F.; Furst J.; Garuoliene K.; Poluzzi E.; Slaby J.; Yahni C.Z.; Altini M.; Fantini M.P.; Koci V.; McTaggart S.; Pontes C.; Reno C.; Rosa S.; Pedrola M.T.; Udovic M.; Wettermark B., Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study, «PHARMACOEPIDEMIOLOGY AND DRUG SAFETY», 2022, 31, pp. 1046 - 1055 [articolo]Open Access
Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F., Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, «JN. JOURNAL OF NEPHROLOGY», 2022, 35, pp. 1017 - 1027 [articolo]Open Access
Salvatore Crisafulli; Elisabetta Poluzzi; Carlotta Lunghi; Vincenzo Di Francesco; Luca Pellizzari; Luca Pasina; Chiara Elli; Francesco Trotta; Agnese Cangini; Caterina Trevisan; Maria Beatrice Zazzara; Graziano Onder; Gianluca Trifir{\`{o}}, Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective, «FRONTIERS IN DRUG SAFETY AND REGULATION», 2022, 2, Article number: 1011701, pp. 1 - 21 [articolo]
Raschi E.; Diemberger I.; Sabatino M.; Poluzzi E.; De Ponti F.; Potena L., Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction, «EXPERT OPINION ON PHARMACOTHERAPY», 2022, 23, pp. 303 - 320 [articolo]
Carlotta Lunghi; Michèle Dugas; Jacinthe Leclerc; Elisabetta Poluzzi; Cathy Martineau; Valérie Carnovale; Théo Stéfan; Patrick Blouin; Johanie Lépine; Laura Jalbert; Nataly R Espinoza Suarez; Olha Svyntozelska; Marie-Pier Dery; Giraud Ekanmian; Daniele Maria Nogueira; Pelumi Samuel Akinola; Stéphane Turcotte; Becky Skidmore; Annie LeBlanc;, Global prevalence of antidepressant utilization in the community: A protocol for a systematic review, «BMJ OPEN», 2022, 12, Article number: e062197, pp. 1 - 5 [articolo]Open Access
Martini, Silvia; Vitali, Francesca; Capelli, Irene; Donadei, Chiara; Raschi, Emanuel; Aiello, Valeria; Corvaglia, Luigi; De Ponti, Fabrizio; Poluzzi, Elisabetta; Galletti, Silvia, Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants, «PEDIATRIC RESEARCH», 2022, 91, pp. 1715 - 1722 [articolo]
